Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same author

Spatially resolved T cell receptor tracking reveals γδT cell localization to tumor-rich regions in high-risk neuroblastoma: A Report from the Children's Oncology Group.

medRxiv : the preprint server for health sciences·2026
Same author

Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma.

Translational oncology·2026
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Chasing ctDNA in Patients With Sarcoma.

Catherine C Coombs1, Tony Dickherber2, Brian D Crompton3

  • 1University of North Carolina at Chapel Hill, Chapel Hill, NC.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 30, 2020
PubMed
Summary
This summary is machine-generated.

Liquid biopsies offer noninvasive cancer profiling but face challenges in rare cancers like sarcomas. This review addresses technical hurdles and discusses future applications in sarcoma care.

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.0K
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.2K

Related Experiment Videos

Last Updated: Dec 17, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.0K
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.2K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Research

Background:

  • Liquid biopsies analyze tumor DNA from body fluids for cancer profiling.
  • These assays are crucial for prognosis, therapy selection, and monitoring in oncology.
  • Application in rare cancers, including sarcomas, has been limited.

Purpose of the Study:

  • To review technical challenges of applying liquid biopsy technologies to sarcomas.
  • To provide an update on the progress in liquid biopsy for sarcoma.
  • To discuss pitfalls in interpreting liquid biopsy data and its clinical integration.

Main Methods:

  • Review of current literature on liquid biopsy technologies and sarcoma.
  • Analysis of technical challenges specific to sarcoma liquid biopsies.
  • Discussion of clinical implications and emerging commercial assays.

Main Results:

  • Liquid biopsies show promise but face significant technical challenges in sarcoma detection and analysis.
  • Progress is being made, but interpretation requires careful consideration of pitfalls.
  • The integration of liquid biopsies into sarcoma clinical care is an evolving area.

Conclusions:

  • Overcoming technical challenges is key to unlocking the potential of liquid biopsies in sarcoma.
  • Standardized protocols and careful data interpretation are essential for clinical utility.
  • Liquid biopsies are poised to become valuable tools in the management of sarcoma patients.